Quantitative analysis of the dystrophin gene by real-time PCR | Zendy

Nela Maksimović | Zendy; Ana Andjelković | Zendy; Vedrana Milić-Rašić | Zendy; Vidosava Rakočević-Stojanović | Zendy; Biljana Kastratović-Kotlica | Zendy; Slavko Brankovic | Zendy; Tatjana Damnjanović | Zendy; Biljana Jekić | Zendy; Vera Bunjevački | Zendy; Ljiljana Luković | Zendy; Dijana Perović | Zendy; Suzana Cvjeticanin | Zendy; Ivaovaković | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Quantitative analysis of the dystrophin gene by real-time PCR

Author(s) -

Nela Maksimović,

Ana Andjelković,

Vedrana Milić-Rašić,

Vidosava Rakočević-Stojanović,

Biljana Kastratović-Kotlica,

Slavko Brankovic,

Tatjana Damnjanović,

Biljana Jekić,

Vera Bunjevački,

Ljiljana Luković,

Dijana Perović,

Suzana Cvjeticanin,

Ivaovaković

Publication year - 2012

Publication title -

archives of biological sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.217

H-Index - 25

eISSN - 1821-4339

pISSN - 0354-4664

DOI - 10.2298/abs1202787m

Subject(s) - duchenne muscular dystrophy , dystrophin , exon , gene , muscular dystrophy , real time polymerase chain reaction , biology , microbiology and biotechnology , genetics , bioinformatics

Duchenne and Becker muscular dystrophy (DMD/BMD) are severe X-linked neuromuscular disorders caused by mutations in the dystrophin gene. Our aim was to optimize a quantitative real-time PCR method based on SYBR® Green I chemistry for routine diagnostics of DMD/BMD deletion carriers. Twenty female relatives of DMD/BMD patients with previously detected partial gene deletions were studied. The relative quantity of the target exons was calculated by a comparative threshold cycle method (ΔΔCt). The carrier status of all subjects was successfully determined. The gene dosage ratio for non-carriers was 1.07±0.20, and for carriers 0.56±0.11. This assay proved to be simple, rapid, reliable and cost-effective

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research